P/B
0,9
Immuron
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
$6.7M
Market Cap • 11/6/2026
1994
(32 years)
Founded
2007
(19 years ago)
IPO
NASDAQ
Listing Exchange
Australia
Country
Valuation
P/S
1,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1
EPS
—
Market Cap
Market Cap
6,7M
EV
475,7K
EV/Revenue
0,1
EV/EBITDA
-0,2
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-72,4%
Total Yield
-72,4%
Payout
0%
Retained Earnings
-58,7M
Profitability
Gross Margin
64,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
25,1%
Capex/Revenue
0,1%
Capex/D&A
11,2%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
1,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
117,6%
CAGR Op. Income 5Y
-15,8%
CAGR Net Income 5Y
-16,6%
CAGR EPS 5Y
-21,3%
CAGR OCF 5Y
-5,9%
Leverage
N.D./EBITDA
2,4
Debt/Equity
0%
Current Ratio
7,3
Quick Ratio
5,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!